Personalizing Mediterranean Diet in Children.

NCT ID: NCT03627923

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-27

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigating glucose response to Mediterranean and regular diets in healthy children in order to develop specific pediatric machine-learning for predicting the personalized glucose response to food for individual children.

The prediction will be based on multiple measurements, including blood tests, personal lifestyle and gut microbiome. This will allow investigators to design personalized Mediterranean machine-learning-based diets which may potentially reduce the burden of disease in adulthood as well as the burden of obesity in the pediatric age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Early-life nutrition plays a critical role in mid-term and long-term metabolic and nutritional outcomes. However, the mechanisms underlying the effects of early nutrition on health are yet to be fully understood. Recently, it has been shown that alterations in intestinal microbiota and modulation of the immune response induced by food serve as the main mechanisms involved in the development of inflammatory conditions such as asthma, inflammatory bowel diseases, and cardiovascular disease. The Mediterranean diet has been shown to reduce the risk of cardiovascular disease, cancer, depression, colorectal cancer, diabetes, obesity, asthma, cognitive decline and premature death in general. Some studies also reported a positive effect of Mediterranean diet on glycemic control. However, whether this diet is a benefit to all individuals is unknown. Likewise, whether gut microbiome and its responses to diet is involved in these effects, or whether different Mediterranean diets may be optimized at the individualized level remains unstudied.

Recently, the investigators developed an algorithm enabling to predict the personalized postprandial glucose responses to food in adult healthy individuals. However, personalized nutrition was never tested on children.

In this study, children will be followed up in different bio-geographical locations. The primary aim of the study is to develop specific pediatric algorithms for predicting the personalized glucose response to food for individual children. This prediction will be based on multiple measurements, including blood and urine tests, anthropometric measurements, personal lifestyle and gut microbiome. This may allow the investigators to design personalized Mediterranean algorithm-based diets which may potentially reduce the burden of non-communicable disease in adulthood as well as the burden of obesity in the pediatric age.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Personalized Nutrition In Children Glucose, High Blood Diet Habit

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Postprandial glucose response Mediterranean diet Personalized nutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy children
* 6-11 years of age
* Tanner 1

Exclusion Criteria

* Acute disease 2 months prior to enrollment
* Chronic illness in the past 5 years, including inflammatory, metabolic, neoplastic, congenital and infectious disease.
* Use of medications (e.g. Antibiotics/antifungal, PPI, analgesics) and any antibiotics 3 months prior to the first visit, PPI one month prior to the beginning of the study or use of medication during the study.
* Treatment with anti-diabetic medications;
* Neuro-psychiatric disorders
* Cancer and recent anticancer treatment
* Eating disorders (Anorexia nervosa. Bulimia nervosa. Binge eating disorder, Night eating syndrome).
* Inability of the participant and/or nuclear family to follow and utilize the smartphone application.
* Dietary restrictions or specific dietary regimen
Minimum Eligible Age

6 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Schneider Children's Medical Center, Israel

OTHER

Sponsor Role collaborator

University of Naples

OTHER

Sponsor Role collaborator

Weizmann Institute of Science

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eran Elinav

Prof. Eran Elinav

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eran Elinav, Prof

Role: PRINCIPAL_INVESTIGATOR

Weizmann Institute of Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Weizmann Institute of Science

Rehovot, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aurelie Bukimer Mimran

Role: CONTACT

Phone: +97289529089

Email: [email protected]

Shimrit Eliyahu miller

Role: CONTACT

Phone: +97289529089

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

aurelie Bukimer mimran

Role: primary

Shimrit Eliyahu miller

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0694-17-RMC

Identifier Type: -

Identifier Source: org_study_id